Background: Infant Neurological International Battery (INFANIB) is one of the common neurological assessment used for the infants. The reliability in the newborns is more essential to prove because INFANIB is used to predict the infant motor capabilities at later stages.
Objective: Objective of the study is to establish intra-rater and inter-rater reliability of Infant Neurological International Battery between normal and high risk term neonates.
Methods: In this cross sectional study a convenience sample of term neonates was included. Demographic data were completed from medical records. Rater one administered INFANIB on all the neonates and the assessments were being videotaped. The videos were anonymized and were viewed by two independent raters so they were blinded from knowing the groups from which each neonate belonged to. Rater three viewed 50 videos randomly for assessment of intra-rater agreement after one month. All the raters were blinded from scores of one another as well to avoid bias during assessment. For intra- as well as inter-rater reliability, two-way mixed, absolute agreement and single measure ICC was calculated.
Results: 112 neonates (normal=56; high risk=56) with mean (SD) gestational age of 39.1 (1.1) and 38.9 (1.1) weeks respectively on mean post natal day of 4 were assessed. For intra-rater agreement the ICC was 0.42 (0.05-0.7) for normal neonates and 0.33 (0-0.63) for high risk neonates. For inter-rater agreement the ICC was 0.1 (0-0.26) for normal neonates and 0.28 (0.05-0.5) for high risk neonates.
Conclusion: The intra-rater and inter-rater reliability of INFANIB proved to be poor between the normal and high risk term neonates. Formal training should be given to any profession or health workers who are planning to use INFANIB as a screening tool for early neurodevelopmental delay among neonates to improve the inter-rater agreement.
Neonatology, Neurodevelopment, Reliability, INFANIB, Screening
Clinical Evaluation of the Rapid STANDARD Q COVID-19 Ag Test for the Screening of Severe Acute Respiratory Syndrome Coronavirus 2.
Kim HW, Park M, Lee JH
Annals of laboratory medicine. 2022; 42(1): 100-104
Clinical Performance of Two Automated Immunoassays, EliA CTD Screen and QUANTA Flash CTD Screen Plus, for Antinuclear Antibody Screening.
Yoon S, Moon HW, Kim H, Hur M, Yun YM
Annals of laboratory medicine. 2022; 42(1): 63-70
The Discovery of Peptide Macrocycle Rescuers of Pathogenic Protein Misfolding and Aggregation by Integrating SICLOPPS Technology and Ultrahigh-Throughput Screening in Bacteria.
Delivoria DC, Skretas G
Methods in molecular biology (Clifton, N.J.). 2022; 2371(): 215-246
3D and 4D Tumorigenesis Model for the Quantitative Analysis of Cancer Cell Behavior and Screening for Anticancer Drugs.
Wessels D, Lusche DF, Voss E, Soll DR
Methods in molecular biology (Clifton, N.J.). 2022; 2364(): 299-318
RNAi Feeding Bioassay: A Protocol for dsRNA Screening Against Asian Citrus Psyllid and Related Hemipteran Insects.
Dos Santos Silva J, de Santana Cerqueira LR, Hunter WB, de Andrade EC
Methods in molecular biology (Clifton, N.J.). 2022; 2360(): 85-90